For the year ending 2025-12-31, TOVX had $1,397K increase in cash & cash equivalents over the period. -$16,704K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -23,739 |
| Stock-based compensation | 654 |
| Change in fair value of contingent consideration | 9,031 |
| Loss on asset disposal | 1 |
| Non - cash lease expense | 522 |
| Depreciation | 108 |
| Deferred research and development tax credit | -188 |
| Prepaid expenses and other current assets | -456 |
| Accounts payable | 69 |
| Accrued expenses | -2,277 |
| Accrued employee benefits | -744 |
| Operating lease liability | -562 |
| Net cash used in operating activities | -16,669 |
| Purchases of property and equipment | 35 |
| Net cash used in investing activities | -35 |
| Payment of loans payable | -70 |
| Proceeds from issuance under at - the - market offering, net of issuance cost | 6,833 |
| Payment of contingent consideration | -1,000 |
| Proceeds from issuance common stock and warrants offering, net of issuance costs | 6,690 |
| Proceeds from warrant inducement | 3,942 |
| Proceeds from long term debt | 1,507 |
| Proceeds from issuance of common stock for warrant exercises | 4 |
| Tax credit receivable | 287 |
| Net cash provided by financing activities | 18,193 |
| Effects of exchange rate changes on cash and cash equivalents | -92 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 1,397 |
| Cash and cash equivalents and restricted at the beginning of this period | 11,705 |
| Cash and cash equivalents and restricted cash at the end of this period | 13,102 |
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)